Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc.BBOT · Entity 5215 | COO & Principal Financial Ofcr | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Oncology Therapeutics, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,152 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Tax withholding · Disposed 343 · Balance 14,152 F1: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 5, 2026 20:13 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | Tax withholdingCommon Stock | 343 | $3.94 | $1,351.42 |
DisclosureSEC source: 0001193125-26-414131 · ownership.xml · nonDerivative · entry 1 Elmelech Idan · CIK 0002058437 · COO & Principal Financial Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,152 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:00 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | Tax withholdingCommon Stock | 343 | $7.80 | $2,675.40 |
DisclosureSEC source: 0001193125-26-296503 · ownership.xml · nonDerivative · entry 1 Elmelech Idan · CIK 0002058437 · COO & Principal Financial Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,495 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| May 10, 2026 Filed May 12, 2026 20:12 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | GrantStock Option (Right to Buy) · Derivative | 758,222 | $0.00 Strike: $7.66 | $0.00 |
DisclosureSEC source: 0001193125-26-219447 · ownership.xml · derivative · entry 1 Elmelech Idan · CIK 0002058437 · COO & Principal Financial Ofcr 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 758,222 Underlying: Common Stock · 758,222 shares Expires 2036-05-09 F1 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 20, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.